Bevacizumab in advanced ovarian cancer: when, what for and why?
Treatment of advanced ovarian cancer remains a complex problem, which generates interest in researchers. Since there have been no changes in standard cytostatic treatment for last 20 years, addition of targeted drugs to the first-line therapy is considered to be a perspective approach. Currently the...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26965 |